Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Performance of a neuro-fuzzy model in predicting weight changes of chronic schizophrenic patients exposed to antipsychotics

Abstract

Artificial intelligence has become a possible solution to resolve the problem of loss of information when complexity of a disease increases. Obesity phenotypes are observable clinical features of drug-naive schizophrenic patients. In addition, atypical antipsychotic medications may cause these unwanted effects. Here we examined the performance of neuro-fuzzy modeling (NFM) in predicting weight changes in chronic schizophrenic patients exposed to antipsychotics. Two hundred and twenty inpatients meeting DSMIV diagnosis of schizophrenia, treated with antipsychotics, either typical or atypical, for more than 2 years, were recruited. All subjects were assessed in the same study period between mid-November 2003 and mid-April 2004. The baseline and first visit’s physical data including weight, height and circumference were used in this study. Clinical information (Clinical Global Impression and Life Style Survey) and genotype data of five single nucleotide polymorphisms were also included as predictors. The subjects were randomly assigned into the first group (105 subjects) and second group (115 subjects), and NFM was performed by using the FuzzyTECH 5.54 software package, with a network-type structure constructed in the rule block. A complete learned model trained from merged data of the first and second groups demonstrates that, at a prediction error of 5, 93% subjects with weight gain were identified. Our study suggests that NFM is a feasible prediction tool for obesity in schizophrenic patients exposed to antipsychotics, with further improvements required.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Ramesh AN, Kambhampati C, Monson JR, Drew PJ . Artificial intelligence in medicine. Ann R Coll Surg Engl 2004; 86: 334–338.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Serretti A, Smeraldi E . Neural network analysis in pharmacogenetics of mood disorders. BMC Med Genet 2004; 5: 27.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Sproule BA, Naranjo CA, Turksen IB . Fuzzy pharmacology: theory and applications. Trends Pharmacol Sci 2002; 23: 412–417.

    Article  CAS  PubMed  Google Scholar 

  4. Phares DA, Halverstadt AA, Shuldiner AR, Ferrell RE, Douglass LW, Ryan AS et al. Association between body fat response to exercise training and multilocus ADR genotypes. Obes Res 2004; 12: 807–815.

    Article  CAS  PubMed  Google Scholar 

  5. Ang KK, Quek C . RSPOP: Rough Set-Based Pseudo Outer-Product Fuzzy Rule Identification Algorithm. Neural Comput 2005; 17: 205–243.

    Article  PubMed  Google Scholar 

  6. Abraham A . Adaptation of fuzzy inference system using neural, learning. In: Nedjah N, Macedo Mourelle L (eds). Fuzzy System Engineering: Theory and Practice; Studies in Fuzziness and Soft Computing, Springer Verlag: Germany, 2005, Chapter 3, pp 53–83.

    Google Scholar 

  7. Lin CT, Lee CSG . Neural Fuzzy Systems: A Neuro-Fuzzy Synergism to Intelligent Systems. Prentice Hall: Upper Saddle River, NJ, 1996.

    Google Scholar 

  8. Kosko B . Neural Networks and Fuzzy Systems: A Dynamical Systems Approach to Machine Intelligence. Prentice Hall: Englewood Cliffs, NJ, 1992.

    Google Scholar 

  9. Davey RC . The obesity epidemic: too much food for thought? Br J Sports Med 2004; 38: 360–363.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Golay A, Masciangelo ML . Burden of obesity: from epidemic to costs. Rev Med Suisse 2005; 1: 807–813.

    CAS  PubMed  Google Scholar 

  11. Catapano L, Castle D . Obesity in schizophrenia: what can be done about it? Australas Psychiatry 2004; 12: 23–25.

    Article  PubMed  Google Scholar 

  12. Merriman S, Haw C, Kirk J, Stubbs J . Risk factors for coronary heart disease among inpatients who have mild intellectual disability and mental illness. J Intellect Disabil Res 2005; 49: 309–316.

    Article  CAS  PubMed  Google Scholar 

  13. Thakore JH . Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry Suppl 2004; 47: S76–S79.

    Article  PubMed  Google Scholar 

  14. Sussman N . The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol 2003; 23: S21–S26.

    CAS  PubMed  Google Scholar 

  15. Lin YC, Yen LL, Chen SY, Kao MD, Tzeng MS, Huang PC et al. Prevalence of overweight and obesity and its associated factors. Findings from National Nutrition and Health Survey in Taiwan, 1993–1996. Prev Med 2003; 37: 233–241.

    Article  PubMed  Google Scholar 

  16. Hsiao CC, Ree SC, Chiang YL, Yeh SS, Chen CK . Obesity in schizophrenic outpatients receiving antipsychotics in Taiwan. Psychiatry Clin Neurosci 2004; 58: 403–409.

    Article  PubMed  Google Scholar 

  17. Lin CC, Bai YM, Wang YC, Chen JY, Liou YJ, Lin CY et al. Artificial neural network prediction of therapeutic response to clozapine with clinical and genetic factors. Eur Neuropsychopharmacol 2004; 14: 282.

    Article  Google Scholar 

  18. Nie J, Linkens DA . Fuzzy-Neural Control. Prentice Hall: London, 1995.

    Google Scholar 

  19. Rosmond R, Bouchard C, Bjorntorp P . Increased abdominal obesity in subjects with a mutation in the 5-HT(2A) receptor gene promoter. Ann N Y Acad Sci 2002; 967: 571–575.

    Article  CAS  PubMed  Google Scholar 

  20. Aubert R, Betoulle D, Herbeth B, Siest G, Fumeron F . 5-HT2A receptor gene polymorphism is associated with food and alcohol intake in obese people. Int J Obes Relat Metab Disord 2000; 24: 920–924.

    Article  CAS  PubMed  Google Scholar 

  21. Hinney A, Ziegler A, Nothen MM, Remschmidt H, Hebebrand J . 5-HT2A receptor gene polymorphisms, anorexia nervosa, and obesity. Lancet 1997; 350: 1324–1325.

    Article  CAS  PubMed  Google Scholar 

  22. Santos JL, Ochoa MC, Patino A, Azcona C, Martinez JA, Marti A . No evidence of association between the serotonin 2A receptor—1438G/A promoter polymorphism and childhood obesity in a Spanish population: a case-parent study and a matched case-control study. Nutr Neurosci 2005; 8: 207–211.

    Article  CAS  PubMed  Google Scholar 

  23. Vickers SP, Easton N, Webster LJ, Wyatt A, Bickerdike MJ, Dourish CT et al. Oral administration of the 5-HT2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology 2003; 167: 274–280.

    Article  CAS  PubMed  Google Scholar 

  24. De Luca V, Mueller DJ, de Bartolomeis A, Kennedy JL . Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol 2007; 12: 1–8.

    Google Scholar 

  25. Ukkola O, Perusse L, Chagnon YC, Despres JP, Bouchard C . Interactions among the glucocorticoid receptor, lipoprotein lipase and adrenergic receptor genes and abdominal fat in the Quebec Family Study. Int J Obes Relat Metab Disord 2001; 25: 1332–1339.

    Article  CAS  PubMed  Google Scholar 

  26. Garenc C, Perusse L, Chagnon YC, Rankinen T, Gagnon J, Borecki IB et al. The alpha 2-adrenergic receptor gene and body fat content and distribution: the HERITAGE Family Study. Mol Med 2002; 8: 88–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Dionne IJ, Turner AN, Tchernof A, Pollin TI, Avrithi D, Gray D et al. Identification of an interactive effect of beta3- and alpha2b-adrenoceptor gene polymorphisms on fat mass in Caucasian women. Diabetes 2001; 50: 91–95.

    Article  CAS  PubMed  Google Scholar 

  28. Linne Y, Dahlman I, Hoffstedt J . Beta1-adrenoceptor gene polymorphism predicts long-term changes in body weight. Int J Obes Relat Metab Disord 2005; 29: 458–462.

    Article  CAS  Google Scholar 

  29. Dionne IJ, Garant MJ, Nolan AA, Pollin TI, Lewis DG, Shuldiner AR et al. Association between obesity and a polymorphism in the beta(1)-adrenoceptor gene (Gly389Arg ADRB1) in Caucasian women. Int J Obes Relat Metab Disord 2002; 26: 633–639.

    Article  CAS  PubMed  Google Scholar 

  30. Pereira AC, Floriano MS, Mota GF, Cunha RS, Herkenhoff FL, Mill JG et al. Beta2 adrenoceptor functional gene variants, obesity, and blood pressure level interactions in the general population. Hypertension 2003; 42: 685–692.

    Article  CAS  PubMed  Google Scholar 

  31. Martinez JA, Corbalan MS, Sanchez-Villegas A, Forga L, Marti A, Martinez-Gonzalez MA . Obesity risk is associated with carbohydrate intake in women carrying the Gln27Glu beta2-adrenoceptor polymorphism. J Nutr 2003; 133: 2549–2554.

    Article  CAS  PubMed  Google Scholar 

  32. Macho-Azcarate T, Marti A, Calabuig J, Martinez JA . Basal fat oxidation and after a peak oxygen consumption test in obese women with a beta2 adrenoceptor gene polymorphism. J Nutr Biochem 2003; 14: 275–279.

    Article  CAS  PubMed  Google Scholar 

  33. Gonzalez Sanchez JL, Proenza AM, Martinez Larrad MT, Ramis JM, Fernandez PC, Palou A et al. The glutamine 27 glutamic acid polymorphism of the beta2-adrenoceptor gene is associated with abdominal obesity and greater risk of impaired glucose tolerance in men but not in women: a population-based study in Spain. Clin Endocrinol 2003; 59: 476–481.

    Article  CAS  Google Scholar 

  34. Lin RCY, Ericsson JO, Benjafield AV, Morris BJ . Association of beta2-adrenoceptor Gln27Glu variant with body weight but not hypertension. Am J Hypertens 2001; 14: 1201–1204.

    Article  CAS  PubMed  Google Scholar 

  35. Ehrenborg E, Skogsberg J, Ruotolo G, Large V, Eriksson P, Arner P et al. The Q/E27 polymorphism in the beta2-adrenoceptor gene is associated with increased body weight and dyslipoproteinaemia involving triglyceride-rich lipoproteins. J Intern Med 2000; 247: 651–656.

    Article  CAS  PubMed  Google Scholar 

  36. Meirhaeghe A, Helbecque N, Cottel D, Amouyel P . Impact of polymorphisms of the human beta2-adrenoceptor gene on obesity in a French population. Int J Obes Relat Metab Disord 2000; 24: 382–387.

    Article  CAS  PubMed  Google Scholar 

  37. Ochoa MC, Marti A, Azcona C, Chueca M, Oyarzabal M, Pelach R et al. Gene-gene interaction between PPAR gamma 2 and ADR beta 3 increases obesity risk in children and adolescents. Int J Obes Relat Metab Disord 2004; 28 (Suppl 3): S37–S41.

    Article  CAS  PubMed  Google Scholar 

  38. Xinli W, Xiaomei T, Meihua P, Song L . Association of a mutation in the beta3-adrenergic receptor gene with obesity and response to dietary intervention in Chinese children. Acta Paediatr 2001; 90: 1233–1237.

    Article  CAS  PubMed  Google Scholar 

  39. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM . Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry 1992; 160 (Suppl 17): 12–16.

    Article  Google Scholar 

  40. Hsu JW, Wang YC, Lin CC, Bai YM, Chen JY, Chiu HJ et al. No evidence for association of alpha 1a adrenoceptor gene polymorphism and clozapine-induced urinary incontinence. Neuropsychobiology 2000; 42: 62–65.

    Article  CAS  PubMed  Google Scholar 

  41. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL . Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001; 62 (Suppl 23): 45–66.

    CAS  PubMed  Google Scholar 

  42. Tsai SJ, Yu YW, Lin CH, Wang YC, Chen JY, Hong CJ . Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment. Neuropsychobiology 2004; 50: 37–40.

    Article  CAS  PubMed  Google Scholar 

  43. Tsai SJ, Wang YC, Yu Younger WY, Lin CH, Yang KH, Hong CJ . Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response. Schizophr Res 2001; 49: 53–58.

    Article  CAS  PubMed  Google Scholar 

  44. Park YM, Chung YC, Lee SH, Lee KJ, Kim H, Byun YC et al. Weight gain associated with the alpha2a-adrenergic receptor −1,291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet 2006; 141: 394–397.

    Article  Google Scholar 

  45. Hoehe MR, Berrettini WH, Schwinn DA, Hsieh WT . A two-allele PstI RFLP for the alpha-1C adrenergic receptor gene (ADRA1C). Hum Mol Genet 1992; 1: 349.

    Article  CAS  PubMed  Google Scholar 

  46. Widen E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC . Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 1995; 333: 348–351.

    Article  CAS  PubMed  Google Scholar 

  47. Lario S, Calls J, Cases A, Oriola J, Torras A, Rivera F . MspI identifies a biallelic polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene. Clin Genet 1997; 51: 129–130.

    Article  CAS  PubMed  Google Scholar 

  48. Collier DA, Arranz MJ, Li T, Mupita D, Brown N, Treasure J . Association between 5-HT2A gene promoter polymorphism and anorexia nervosa. Lancet 1997; 350: 412.

    Article  CAS  PubMed  Google Scholar 

  49. Visscher TL, Seidell JC . Time trends (1993–1997) and seasonal variation in body mass index and waist circumference in the Netherlands. Int J Obes Relat Metab Disord 2004; 28: 1309–1316.

    Article  CAS  PubMed  Google Scholar 

  50. Okajima Y, Togo M, Kitagawa G, Nishikawa S . Time series analysis of monthly body weight and blood pressures of one man from 29 to 65 years. Am J Human Biol 2000; 12: 526–541.

    Article  Google Scholar 

Download references

Acknowledgements

This study was supported by a grant of the Department of Health, Taiwan, in year 2003 to support the establishment of the Evidence-Based Medicine Center, Yu-Li Hospital.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H-J Chiu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lan, T., Loh, E., Wu, M. et al. Performance of a neuro-fuzzy model in predicting weight changes of chronic schizophrenic patients exposed to antipsychotics. Mol Psychiatry 13, 1129–1137 (2008). https://doi.org/10.1038/sj.mp.4002128

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.mp.4002128

Keywords

This article is cited by

Search

Quick links